Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 136.06

-1.4%

Jan 30 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (1817)	1/18/2012 10:58:06 AM
From: Biotech Jim	1 Recommendation Read Replies (1) of 1834

Not much detail on Elagolix via the spoken word. More on the VMAT2 program. Here is a slide summary on the Elagolix ongoing activities: • Finalizing Phase III protocol for endometriosis though an SPA following a very productive series of Type C meetings with FDA » Endpoints – non-menstrual pelvic pain and dysmenorrhea » Statistical Methods – responder analysis » Trial Design – Two trials, placebo controlled, six-months in duration, safety extension to one year » Site qualification ongoing No milestones expected from ABT this year, and the Ph2 uterine fibroids study will be reported on later in 2012. The Ph3 Elagolix programs will be 6 month studies, with safety extensions out to 1 year. The GNRH antagonist program apparently has 2 good backup compounds that may be used for PCOS, polycystic ovarian syndrome. The GNRH compounds seem to have solved the gentox issue that has plagued other efforts in the field (ie, MRK). Finally, NBIX expects to put an IND forward for 1 of thier other discovery programs. I am interested in the undisclosed target for ET, essential tremor. Huge market here IMHO. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next